DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Dalotuzumab is an investigational drug.
There have been 13 clinical trials for Dalotuzumab. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2012.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Colorectal Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Alliance for Clinical Trials in Oncology, and National Cancer Institute (NCI).
Recent Clinical Trials for Dalotuzumab
|A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)||Merck Sharp & Dohme Corp.||Phase 2|
|A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)||Merck Sharp & Dohme Corp.||Phase 2|
|Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1)||Merck Sharp & Dohme Corp.||Phase 1|